BACKGROUND: Developing strategies for managing coronary artery calcification (CAC) in patients with CKD is an important clinical challenge. Experimental studies have demonstrated that magnesium inhibits vascular calcification, whereas the uremic toxin indoxyl sulfate aggravates it. METHODS: To assess the efficacy of magnesium oxide (MgO) and/or the oral carbon adsorbent AST-120 for slowing CAC progression in CKD, we conducted a 2-year, open-label, randomized, controlled trial, enrolling patients with stage 3-4 CKD with risk factors for CAC (diabetes mellitus, history of cardiovascular disease, high LDL cholesterol, or smoking). Using a two-by-two factorial design, we randomly assigned patients to an MgO group or a control group, and to an AST-120 group or a control group. The primary outcome was percentage change in CAC score. RESULTS: We terminated the study prematurely after an interim analysis with the first 125 enrolled patients (of whom 96 completed the study) showed that the median change in CAC score was significantly smaller for MgO versus control (11.3% versus 39.5%). The proportion of patients with an annualized percentage change in CAC score of ≥15% was also significantly lower for MgO compared with control (23.9% versus 62.0%). However, MgO did not suppress the progression of thoracic aorta calcification. The MgO group's dropout rate was higher than that of the control group (27% versus 17%), primarily due to diarrhea. The percentage change in CAC score did not differ significantly between the AST-120 and control groups. CONCLUSIONS: MgO, but not AST-120, appears to be effective in slowing CAC progression. Larger-scale trials are warranted to confirm these findings.
RCT Entities:
BACKGROUND: Developing strategies for managing coronary artery calcification (CAC) in patients with CKD is an important clinical challenge. Experimental studies have demonstrated that magnesium inhibits vascular calcification, whereas the uremic toxin indoxyl sulfate aggravates it. METHODS: To assess the efficacy of magnesium oxide (MgO) and/or the oral carbon adsorbentAST-120 for slowing CAC progression in CKD, we conducted a 2-year, open-label, randomized, controlled trial, enrolling patients with stage 3-4 CKD with risk factors for CAC (diabetes mellitus, history of cardiovascular disease, high LDL cholesterol, or smoking). Using a two-by-two factorial design, we randomly assigned patients to an MgO group or a control group, and to an AST-120 group or a control group. The primary outcome was percentage change in CAC score. RESULTS: We terminated the study prematurely after an interim analysis with the first 125 enrolled patients (of whom 96 completed the study) showed that the median change in CAC score was significantly smaller for MgO versus control (11.3% versus 39.5%). The proportion of patients with an annualized percentage change in CAC score of ≥15% was also significantly lower for MgO compared with control (23.9% versus 62.0%). However, MgO did not suppress the progression of thoracic aorta calcification. The MgO group's dropout rate was higher than that of the control group (27% versus 17%), primarily due to diarrhea. The percentage change in CAC score did not differ significantly between the AST-120 and control groups. CONCLUSIONS:MgO, but not AST-120, appears to be effective in slowing CAC progression. Larger-scale trials are warranted to confirm these findings.
Authors: Parisa Aghagolzadeh; Matthias Bachtler; Rakesh Bijarnia; Christopher Jackson; Edward R Smith; Alex Odermatt; Ramin Radpour; Andreas Pasch Journal: Atherosclerosis Date: 2016-05-27 Impact factor: 5.162
Authors: Juan M Diaz-Tocados; Alan Peralta-Ramirez; María E Rodríguez-Ortiz; Ana I Raya; Ignacio Lopez; Carmen Pineda; Carmen Herencia; Addy Montes de Oca; Noemi Vergara; Sonja Steppan; M Victoria Pendon-Ruiz de Mier; Paula Buendía; Andrés Carmona; Julia Carracedo; Juan F Alcalá-Díaz; Joao Frazao; Julio M Martínez-Moreno; Antonio Canalejo; Arnold Felsenfeld; Mariano Rodriguez; Escolástico Aguilera-Tejero; Yolanda Almadén; Juan R Muñoz-Castañeda Journal: Kidney Int Date: 2017-07-29 Impact factor: 10.612
Authors: An S De Vriese; Rogier Caluwé; Lotte Pyfferoen; Dirk De Bacquer; Koen De Boeck; Joost Delanote; Didier De Surgeloose; Piet Van Hoenacker; Bruno Van Vlem; Francis Verbeke Journal: J Am Soc Nephrol Date: 2019-11-08 Impact factor: 10.121
Authors: Peter Lanzer; Fadil M Hannan; Jan D Lanzer; Jan Janzen; Paolo Raggi; Dominic Furniss; Mirjam Schuchardt; Rajesh Thakker; Pak-Wing Fok; Julio Saez-Rodriguez; Angel Millan; Yu Sato; Roberto Ferraresi; Renu Virmani; Cynthia St Hilaire Journal: J Am Coll Cardiol Date: 2021-09-14 Impact factor: 27.203
Authors: Mi Jung Lee; Jung Tak Park; Tae Ik Chang; Young Su Joo; Tae-Hyun Yoo; Sue Kyung Park; Wookyung Chung; Yong-Soo Kim; Soo Wan Kim; Kook-Hwan Oh; Shin-Wook Kang; Kyu Hun Choi; Curie Ahn; Seung Hyeok Han Journal: Clin J Am Soc Nephrol Date: 2021-04-20 Impact factor: 10.614
Authors: Antonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Mario Cozzolino; Biagio Raffaele Di Iorio Journal: Cells Date: 2021-05-03 Impact factor: 6.600